Player FM - Internet Radio Done Right
94 subscribers
Checked 2d ago
Added eight years ago
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Podcasts Worth a Listen
SPONSORED
W
We Have The Receipts


1 Battle Camp S1: Reality Rivalries with Dana Moon & QT 1:00:36
1:00:36
Play Later
Play Later
Lists
Like
Liked1:00:36
Do you have fond childhood memories of summer camp? For a chance at $250,000, campers must compete in a series of summer camp-themed challenges to prove that they are unbeatable, unhateable, and unbreakable. Host Chris Burns is joined by the multi-talented comedian Dana Moon to recap the first five episodes of season one of Battle Camp . Plus, Quori-Tyler (aka QT) joins the podcast to dish on the camp gossip, team dynamics, and the Watson to her Sherlock Holmes. Leave us a voice message at www.speakpipe.com/WeHaveTheReceipts Text us at (929) 487-3621 DM Chris @FatCarrieBradshaw on Instagram Follow We Have The Receipts wherever you listen, so you never miss an episode. Listen to more from Netflix Podcasts.…
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty Lecture)
Manage episode 478840261 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:
- Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
- Comparing safety profiles of CDK4/6 inhibitors (9:49)
- Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
- Real-world evidence with CDK4/6 inhibitors (27:31)
1552 episodes
Manage episode 478840261 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:
- Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
- Comparing safety profiles of CDK4/6 inhibitors (9:49)
- Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
- Real-world evidence with CDK4/6 inhibitors (27:31)
1552 episodes
All episodes
×R
Research To Practice | Oncology Videos

1 Chronic Lymphocytic Leukemia | Paolo Ghia, MD, PhD 32:31
32:31
Play Later
Play Later
Lists
Like
Liked32:31
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications…
R
Research To Practice | Oncology Videos

1 For Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS Congress 1:31:27
1:31:27
Play Later
Play Later
Lists
Like
Liked1:31:27
Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O’Malley and Dr Shannon N Westin, including the following topics: Introduction: Overview of Ovarian Cancer (OC) Management (0:00) Genetic Testing for Newly Diagnosed Advanced OC (14:31) Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46) Other Available and Investigational Novel Strategies for OC (43:56) Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24) NCPD information and select publications…
R
Research To Practice | Oncology Videos

1 Prostate Cancer — Fourth Annual National General Medical Oncology Summit 47:34
47:34
Play Later
Play Later
Lists
Like
Liked47:34
Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics: Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00) Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14) CME information and select publications
R
Research To Practice | Oncology Videos

1 Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies 1:56:58
1:56:58
Play Later
Play Later
Lists
Like
Liked1:56:58
Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics: Introduction (0:00) Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24) Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51) Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit 48:55
48:55
Play Later
Play Later
Lists
Like
Liked48:55
Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Oncology Nursing Update: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:03
1:33:03
Play Later
Play Later
Lists
Like
Liked1:33:03
Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications…
R
Research To Practice | Oncology Videos

1 Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy 52:53
52:53
Play Later
Play Later
Lists
Like
Liked52:53
Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion… 32:02
32:02
Play Later
Play Later
Lists
Like
Liked32:02
Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates 44:21
44:21
Play Later
Play Later
Lists
Like
Liked44:21
Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28) Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39) Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44) Data surrounding adjuvant immunotherapy for MIBC (38:07) Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44) Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06) Implementation of emerging data in the treatment landscape of UC (41:56) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies 40:11
40:11
Play Later
Play Later
Lists
Like
Liked40:11
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications…
R
Research To Practice | Oncology Videos

1 EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit 52:18
52:18
Play Later
Play Later
Lists
Like
Liked52:18
Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics: Introduction (0:00) Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42) Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25) CME information and select publications…
R
Research To Practice | Oncology Videos

1 HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit 1:39:35
1:39:35
Play Later
Play Later
Lists
Like
Liked1:39:35
Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O’Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2 58:21
58:21
Play Later
Play Later
Lists
Like
Liked58:21
Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications…
R
Research To Practice | Oncology Videos

1 Ovarian Cancer — Proceedings from a Session Held During the 2025 SGO Annual Meeting on Women’s Cancer® 1:29:33
1:29:33
Play Later
Play Later
Lists
Like
Liked1:29:33
Featuring perspectives from Dr Kathleen N Moore, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Shannon N Westin, moderated by Dr Secord, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Westin (2:42) Management of Relapsed/Refractory OC — Dr Secord (23:06) Novel Investigational Therapies for Advanced OC — Dr Moore (46:55) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Salani (1:08:34) CME information and select publications…
R
Research To Practice | Oncology Videos

1 Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 43:18
43:18
Play Later
Play Later
Lists
Like
Liked43:18
Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.